1. Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants. Issue 2 (30th November 2022) Authors: Kalluri, Hari V.; Rosebraugh, Matthew R.; Misko, Thomas P.; Ziemann, Adam; Liu, Wei; Cree, Bruce A. C. Journal: Annals of neurology Issue: Volume 93:Issue 2(2023) Page Start: 285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗